Cytotoxic therapy for prostate cancer

par I. G. Rusakov, S. V. Mishugin
Publié 2018-11-01

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

par A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Publié 2014-09-01

DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER

par S. V. MISHUGIN, A. A. GRITSKEVICH, I. G. RUSAKOV
Publié 2016-12-01

POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER

par A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Publié 2017-06-01

THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER

par A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Publié 2017-06-01

POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER

par A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Publié 2017-06-01

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

par A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Publié 2014-11-01

Mesto khimioterapii i gormonoterapii vo 2-y linii lecheniya kastratsionno-rezistentnogo raka predstatel'noy zhelezy

par I G Rusakov, A A Gritskevich, S V Mishugin
Publié 2012-09-01

Еfficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer

par I. G. Rusakov, A. A. Gritskevich, T. P. Baitman, S. V. Mishugin
Publié 2020-12-01

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy

par I. G. Rusakov, A. A. Gritskevich, T. P. Baitman, S. V. Mishugin
Publié 2020-12-01

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER

par T. N. Skvortsova, S. V. Mishugin, A. A. Gritskevich, I. G. Rusakov
Publié 2017-01-01

The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors

par А. А. Gritskevich, I. G. Rusakov, Т. Р. Baitman, S. V. Mishugin
Publié 2021-06-01

Study of the economic efficiency of the combined method of Octreotide-depo + dexamethasone therapy in the treatment of patients with castration-resistant prostate cancer

par S. V. Mishugin, I. G. Rusakov, I. V. Novikova, A. A. Gritskevich
Publié 2019-06-01

CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER

par A. A. GRITSKEVICH, S. V. MISHUGIN, A. A. TEPLOV, I. G. RUSAKOV
Publié 2016-12-01

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESIS...

par S. V. Mishugin, A. A. Gritskevich, A. A. Mordovin, I. G. Rusakov
Publié 2017-11-01

The role of sunitinib in the therapy of metastatic renal cell carcinoma

par I. G. Rusakov, A. A. Gritskevich, T. P. Baitman, A. N. Shipilova, S. V. Mishugin
Publié 2020-07-01

Effective suppression of testosterone: the best castration therapy for hormone-sensitive prostate cancer?

par A. A. Gritskevich, S. V. Mishugin, A. A. Teplov, V. L. Medvedev, I. G. Rusakov
Publié 2015-12-01

The role of prostate-specific antigen in the prediction of hormone-sensitive prostate cancer

par A. A. Gritskevich, S. V. Mishugin, A. A. Teplov, V. L. Medvedev, I. G. Rusakov
Publié 2015-12-01

EVALUATION OF EFFICACY OF BUSERELIN-DEPO IN PATIENTS WITH LOCALLY ADVANCED AND METHASTATIC PROSTATE CANCER

par S. V. MISHUGIN, A. A. DROBYAZKO, A. A. MORDOVIN, A. A. GRICKEVICH, I. G. RUSAKOV
Publié 2017-06-01

The role of Buserelin in the treatment of advanced prostate cancer (APC)

par S. V. Mishugin, A. A. Drobyazko, A. A. Mordovin, A. A. Gritskevich, I. G. Rusakov
Publié 2015-12-01